Analysis of the offer and effectiveness of prophylaxis to sexual pre-exposure (PrEP) to fight HIV/AIDS in Brazil
DOI:
https://doi.org/10.33448/rsd-v10i12.19095Keywords:
Public health; Prep; HIV.Abstract
The HIV/AIDS virus epidemic is considered a phenomenon of large proportions and, due to its pandemic character and severity, represents a major public health problem, lacking more humanized and efficient policies, and in this sense, one of the mos recent methods of prophylaxis to sexual pre-exposure, this is (PrEP) which is an early pharmacological treatment made through the combination of two drugs, which must be taken daily by the user before he has the virus infection. Thus, this article proposes a reflection on the challenges of the offer and effectiveness of PrEP to fight HIV in Brazil. Therefore, a theoretical review of exploratory literature on the subject was carried out using the deductive approach method, with the use of bibliographic data of a qualitative nature through documentary research. From this, it was concluded that through the use of prophylaxis, it was possible to reduce the risk of people acquiring the virus infection, as this strategy proved to be quite effective and safe in people at increased risk of acquiring the infection, however, if makes it important that public policies to fight HIV/AIDS in the country are widely publicized and in order to reach the majority of the public that is vulnerable to contagion by the virus.
References
Anderson, P. L., Kiser, J. J., Gardner, E. M., Rower, J. E., Meditz, A., & Grant, R. M. (2011). Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother 66:240-50.
Brasil. Ministério da Saúde. (2020). Boletim Epidemiológico sobre a doença aponta queda na taxa de detecção de Aids no país desde 2012. http://www.aids.gov.br/pt-br/noticias/casos-de-aids-diminuem-no-brasil.
Brasil. Ministério da Saúde. (2018). Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas para Profilaxia Pré-Exposição (PrEP) de Risco à Infecção pelo HIV. Brasília. http://www.aids.gov.br/pt-br/pub/2017/protocolo-clinico-e-diretrizes-terapeuticas-para-profilaxia-pre-exposicao-prep-de-risco.
Brasil. Ministério da Saúde. (2017). Nota Informativa Nº007/2017 - DDAHV/SVS/MS. http://azt.aids.gov.br/documentos/siclom_operacional/Nota% 20Informativa%20007%20-%20protocolo%20de%20uso%20ARV%20-%202017.pdf
Brasil. Ministério da Saúde. (2016). Boletim Epidemiológico Aids e DST, V, n. 1. www.aids.gov.br/system/tdf/pub/2016/59427/bole tim_2016_1_pdf_16375.pdf?file=1&type=node&id=59427&force=1.
Brasil. Ministério da Saúde. (2015). Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Boletim Epidemiológico HIV/AIDS. Brasília. ano 4, n. 1, 2015. http://www.aids.gov.br/pt-br/pub/2015/boletim-epidemiologico-hivaids.
Brasil. Ministério da Saúde. (2008). Programa Nacional de DST e AIDS: Manual de adesão ao tratamento para pessoas vivendo com HIV e AIDS. Brasília. http://bvsms.saude.gov.br/bvs/publicacoes/manual_adesao_tratamento.
Brito, M. A., Castilho, A. E., & Szwarcwald, L. C. (2001). AIDS e infecção pelo HIV no Brasil: uma epidemia multifacetada artigo de Opinião. Rev. Soc. Bras. Med. Trop. 34(2) abr. https://doi.org/10.1590/S0037-86822001000200010.
Cardoso, G. P., & Arruda, A. (2019). As representações sociais da soropositividade e sua relação com a observância terapêutica. Rev. Ciênc Saúde 14; 10(1). http://www.scielo.br/pdf/csc/v10n1/a16v10n1
Dorin, L. D., Silva, T. B., & Rentes Medeiros, D. (2021). Prevenção ao HIV no Brasil: Representações sociais, estigma e desafios dos usuários da PrEP. Pathos: Revista Brasileira de Práticas Públicas e Psicopatologia, 7(1), ISSN 2447-6137.
Finkelstein, J. L., Gala, P., Rochford, R., Glesby, M. J., & Mehta, S. (2015). HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings. J Int AIDS Soc. 18:19033. https://doi.org/10.7448/IAS.18.1.19033.
Foner, V. A. et al. (2016). Effectiveness and safety of oral HIV pre-exposure prophylaxis for all populations: a systematic review and meta-analysis. AIDS, [S.l.], 30(12).
Fonseca, E. M., (2008). Resposta brasileira à epidemia de HIV/AIDS entre usuários de drogas injetáveis: marcos, avanços e desafios. 139 f. Tese (Doutorado em Saúde Pública) - Escola Nacional de Saúde Pública
Arouca, S. Fundação Oswaldo Cruz. https://www.arca.fiocruz.br/handle/icict/4499.
Grant, R. M. et al. (2017). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The New England Journal of Medicine, [S.l.], 363(27). https://doi.org/10.1056/ NEJMoa1011205
Greco, B. D. (2016). Trinta anos de enfrentamento à epidemia da Aids no Brasil, 1985-2015 Ciênc. saúde colet. 21(5). https://doi.org/10.1590/1413-81232015215.04402016.
Parker, R., & Camargo, K. R. Jr. (2000). Pobreza e HIV/AIDS: aspectos antropológicos e sociológicos. Cadernos de Saúde Pública, 16(Supl. 1).
Portugal, J. (2018) Lancet HIV destaca os resultados do PrEP Brasil. Fiocruz, Comunicação e Informação. Recuperado de https://portal.fiocruz.br/noticia/lancet-hiv-destaca-osresultados-do-prep-brasil
Silva, A. L. C. N., Waidman, M. A. P., & Marcon, S. S. (2009). [Adhesion And Non Adhesion To Anti-Retroviral Therapy: The Two Faces Of A Same Experience]. Rev Bras Enferm. 62(2):213-20. HTTPS://DOI.ORG/10.1590/S0034-71672009000200007.
Zucchi, E. M. et al., (2018). Da evidência à ação: desafios do Sistema Único de Saúde para ofertar a profilaxia pré-exposição sexual (PrEP) ao HIV às pessoas em maior vulnerabilidade. Cad. Saúde Pública 34(7). https://doi.org/10.1590/0102-311X00206617.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 João Marcos Batista Gomes de Araujo; Jose Cardoso dos Santos Neto; Paula Ívina Oliveira Silva Santos; Marina Gentil Heraclio Maia; Pedro Elias Morato; Maria Lidivânia Batista Gomes; José Cândido da Silva Nóbrega; Manoel Marques de Souto Nóbrega Filho
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
